PODD · a US exchange · USD · Market cap $9.3B · 5,400 employees
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Screened 2026-09-10 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Insulet Corporation holds its Markdown at $134.68. Elevated stress, defensive posture warranted, held for 18 days.
As held on the ledger · 2026-09-10
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 18 days
Price at the screen
$134.68
Valuation
25.32 trailing · 17.47 forward price to earnings
Values screen
PASS· score 75.9
Beta
1.08
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.75%
Below 33%
Interest-bearing debt is just 29.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
38.47%
Below 49%
Money owed to the company is 38.5% of assets, under the 49% limit.
Pass
Revenue purity
1.28%
Below 5%
Only 1.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 25% discount to our $168.57 fair value, moderate competitive moat, 23.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 25.2% margin of safety to the base estimate.
Third-party analyst targets: 22 covering, consensus None. The average target sits +24% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Diabetics swap tubes and injections for one pod
Every insulin user knows the daily grind of tubes, site changes and manual calculations. Insulet's Omnipod 5 removes most of that friction and the numbers show adoption accelerating. Revenue is rising 34 percent, return on equity sits at 23 percent and the forward multiple is 20.4 times with a moderate moat protecting the platform.
The shares trade at 164 dollars against our 211 dollar fair value, a 29 percent margin of safety. Profit margins are already 10 percent and 23 analysts carry a strong buy consensus with a 245 dollar median target. The ethical screen clears cleanly on product safety and access.
Growth still depends on insurance coverage and hospital formulary wins, both of which can shift quickly. Competition from larger device makers remains real and any slowdown in new patient starts would hit the top line fast. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PODD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (24 analysts) rates it buy, with a mean price target of $247.
2026-08-09Distribution$139.30-9.1%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (24 analysts) rates it buy, with a mean price target of $247.
2026-07-18Distribution$153.22+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (24 analysts) rates it buy, with a mean price target of $247.
2026-07-03Distribution$153.22+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$153.22Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
